Homologous recombination deficiency (HRD) arises due to a defect in DNA repair and serves as an important therapeutic biomarker. NGS assays that measure HRD status via genomic instability are used to stratify ovarian and breast cancer patients and determine eligibility for clinical trials as well as PARP inhibitor and platinum-based therapies.
Testing is performed on FFPE biopsied tissue, and, despite the challenges of this sample type and the complexity of analysis, there are currently no commercially available HRD reference materials that enable standardization between assays.
This poster from LGC SeraCare describes the development and validation of reference materials to aid in developing and validating NGS-based HRD assays and for quality control monitoring of genomic instability scores.
Offered Free by: LGC SeraCare Life Sciences
See All Resources from: LGC SeraCare Life Sciences